Assembly Biosciences, Inc. (ASMB): Price and Financial Metrics


Assembly Biosciences, Inc. (ASMB): $4.31

-0.06 (-1.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ASMB Stock Summary

  • The ratio of debt to operating expenses for Assembly Biosciences Inc is higher than it is for about only 9.6% of US stocks.
  • Revenue growth over the past 12 months for Assembly Biosciences Inc comes in at 395.55%, a number that bests 98.24% of the US stocks we're tracking.
  • In terms of volatility of its share price, ASMB is more volatile than 95.93% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Assembly Biosciences Inc are PRQR, DRNA, CNCE, AGIO, and QURE.
  • Visit ASMB's SEC page to see the company's official filings. To visit the company's web site, go to www.assemblybio.com.

ASMB Stock Price Chart Interactive Chart >

Price chart for ASMB

ASMB Price/Volume Stats

Current price $4.31 52-week high $27.84
Prev. close $4.37 52-week low $4.01
Day low $4.26 Volume 289,027
Day high $4.45 Avg. volume 1,205,380
50-day MA $4.86 Dividend yield N/A
200-day MA $11.29 Market Cap 172.65M

Assembly Biosciences, Inc. (ASMB) Company Bio


Assembly Biosciences develops oral therapies for intractable infectious diseases in the United States. The company focuses on the hepatitis B virus and C. difficile-associated infections. The company was founded in 2005 and is based in New York, New York.


ASMB Latest News Stream


Event/Time News Detail
Loading, please wait...

ASMB Latest Social Stream


Loading social stream, please wait...

View Full ASMB Social Stream

Latest ASMB News From Around the Web

Below are the latest news stories about Assembly Biosciences Inc that investors may wish to consider to help them evaluate ASMB as an investment opportunity.

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Stocks News Feed

SOUTH SAN FRANCISCO, Calif., March 05, 2021 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 26,000 shares of the Company’s common stock with an exercise price of $5.05… Read More »Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stocks News Feed | March 5, 2021

The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4) AtriCure, Inc. (NASDAQ: ATRC ) Five Prime Therapeutics, Inc. ( NASDAQ: FPRX) - announced a deal to be bought by Amgen Inc. (NASDAQ: AMGN ) for $1.9 billion Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 4) AbCellera Biologics Inc. (NASDAQ: ABCL ) Acutus Medical, Inc. (NASDAQ: AFIB ) ADC Therapeutics SA (NYSE: ADCT ) Aptose Biosciences Inc. (NASDAQ: APTO ) Assembly Biosciences, Inc. (NASDAQ: ASMB ) Athenex, Inc. (NASDAQ: ATNX ) Biophytis SA (NASDAQ: BPTS ) Bioventus Inc. (NASDAQ: BVS ) Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) BriaCell Therapeutics Corp. (NASDAQ: BCTX ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) Dyne Ther...

Benzinga | March 5, 2021

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 26,000 shares of the Company’s common stock with an exercise price of $5.05 per share, the closing price of Assembly Bio’s common stock on March 1, 2021. The stock options were granted as material inducements to the new employees to accept the Company’s offers of employment. The stock options have a ten-year term and vest over four years, with one-fourth vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in approximately equal monthly installm...

Yahoo | March 5, 2021

Arbutus Biopharma (ABUS) Q4 2020 Earnings Call Transcript

Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation fourth-quarter and year-end 2020 financial results and corporate update conference call. Good morning, and thank you for joining the Arbutus Biopharma fourth-quarter 2020 conference call and webcast. On the call today are Bill Collier, president and chief executive officer; Dr. Gaston Picchio, chief development officer; Dr. Michael Sofia, chief scientific officer; and Dave Hastings, chief financial officer.

Yahoo | March 5, 2021

Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy

Assembly Biosciences Inc (NASDAQ: ASMB) will not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive …

Benzinga | February 26, 2021

Read More 'ASMB' Stories Here

ASMB Price Returns

1-mo -0.46%
3-mo -26.70%
6-mo -71.02%
1-year -75.50%
3-year -90.12%
5-year -26.58%
YTD -28.76%
2020 -70.43%
2019 -9.55%
2018 -50.01%
2017 272.43%
2016 61.78%

Continue Researching ASMB

Want to see what other sources are saying about Assembly Biosciences Inc's financials and stock price? Try the links below:

Assembly Biosciences Inc (ASMB) Stock Price | Nasdaq
Assembly Biosciences Inc (ASMB) Stock Quote, History and News - Yahoo Finance
Assembly Biosciences Inc (ASMB) Stock Price and Basic Information | MarketWatch

Page generated in 1.0429 seconds.